Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels
- PMID: 19337257
- PMCID: PMC2670000
- DOI: 10.1038/sj.bjc.6604961
Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels
Abstract
Immunochemical faecal occult blood testing (FIT) provides quantitative test results, which allows optimisation of the cut-off value for follow-up colonoscopy. We conducted a randomised population-based trial to determine test characteristics of FIT (OC-Sensor micro, Eiken, Japan) screening at different cut-off levels and compare these with guaiac-based faecal occult blood test (gFOBT) screening in an average risk population. A representative sample of the Dutch population (n=10 011), aged 50-74 years, was 1 : 1 randomised before invitation to gFOBT and FIT screening. Colonoscopy was offered to screenees with a positive gFOBT or FIT (cut-off 50 ng haemoglobin/ml). When varying the cut-off level between 50 and 200 ng ml(-1), the positivity rate of FIT ranged between 8.1% (95% CI: 7.2-9.1%) and 3.5% (95% CI: 2.9-4.2%), the detection rate of advanced neoplasia ranged between 3.2% (95% CI: 2.6-3.9%) and 2.1% (95% CI: 1.6-2.6%), and the specificity ranged between 95.5% (95% CI: 94.5-96.3%) and 98.8% (95% CI: 98.4-99.0%). At a cut-off value of 75 ng ml(-1), the detection rate was two times higher than with gFOBT screening (gFOBT: 1.2%; FIT: 2.5%; P<0.001), whereas the number needed to scope (NNscope) to find one screenee with advanced neoplasia was similar (2.2 vs 1.9; P=0.69). Immunochemical faecal occult blood testing is considerably more effective than gFOBT screening within the range of tested cut-off values. From our experience, a cut-off value of 75 ng ml(-1) provided an adequate positivity rate and an acceptable trade-off between detection rate and NNscope.
Figures



Similar articles
-
Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.Int J Cancer. 2015 Apr 15;136(8):1827-34. doi: 10.1002/ijc.29187. Epub 2014 Sep 18. Int J Cancer. 2015. PMID: 25195670
-
Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.Eur J Cancer. 2013 Sep;49(14):3049-54. doi: 10.1016/j.ejca.2013.04.023. Epub 2013 May 22. Eur J Cancer. 2013. PMID: 23706981
-
Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.J Med Screen. 2019 Jun;26(2):92-97. doi: 10.1177/0969141318804843. Epub 2018 Oct 18. J Med Screen. 2019. PMID: 30336730
-
Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Gut. 2015. PMID: 26041750 Review.
-
Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.Gut. 2019 May;68(5):873-881. doi: 10.1136/gutjnl-2017-315340. Epub 2018 Jun 22. Gut. 2019. PMID: 29934436
Cited by
-
Secondary prevention at 360°: the important role of diagnostic imaging.Radiol Med. 2015 Jun;120(6):511-25. doi: 10.1007/s11547-014-0484-y. Epub 2015 Jan 9. Radiol Med. 2015. PMID: 25572539
-
Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening.Can J Gastroenterol. 2012 Mar;26(3):131-47. doi: 10.1155/2012/486328. Can J Gastroenterol. 2012. PMID: 22408764 Free PMC article. Review.
-
Performance of the Fecal Immunochemical Test for Colorectal Cancer Screening Using Different Stool-Collection Devices: Preliminary Results from a Randomized Controlled Trial.Gut Liver. 2016 Nov 15;10(6):925-931. doi: 10.5009/gnl15479. Gut Liver. 2016. PMID: 27282262 Free PMC article. Clinical Trial.
-
The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer.Int J Colorectal Dis. 2012 Dec;27(12):1657-64. doi: 10.1007/s00384-012-1518-3. Epub 2012 Jun 14. Int J Colorectal Dis. 2012. PMID: 22696204
-
Screening for colorectal cancer using the faecal occult blood test, Hemoccult.Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD001216. doi: 10.1002/14651858.CD001216.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253456 Free PMC article.
References
-
- Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV (2007) Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 99: 1462–1470 - PubMed
-
- Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996) A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334: 155–159 - PubMed
-
- Brecht JG, Robra BP (1987) A graphic method of estimating the specificity of screening programmes from incomplete follow-up data. Methods Inf Med 26: 53–58 - PubMed
-
- Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P, Zappa M (2002) Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 9: 99–103 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical